Jana Baranda

Mrs. Jana Baranda

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
Christos D. ArgyropoulosChristos D. Argyropoulos
Christos D. Argyropoulos
JLJanina Leckler
Janina Leckler
JSJon Salmanton-García
Jon Salmanton-García
MCMarinos Constantinou
Marinos Constantinou
AAAlexandra Alexandrou
Alexandra Alexandrou
Zoi Dorothea PanaZoi Dorothea Pana
Zoi Dorothea Pana
Background: The pan-European VACCELERATE network aims to implement the first transnational harmonized and sustainable vaccine trial Volunteer Registry, being a single entry point for potential volunteers of large-scale vaccine trials across Europe. This work exhibits a set of harmonized vaccine trial–related educational and promotional tools for the general public, designed and disseminated by the pan-European VACCELERATE network. Objective: This study primarily aimed to design and develop a standard toolkit to increase positive attitudes and access to trustworthy information for better access and increased recruitment to vaccine trials for the public. More specifically, the produced tools are focused on inclusiveness and equity, and are targeting different population groups, including underserved ones, as potential volunteers for the VACCELERATE Volunteer Registry (older individuals, migrants, children, and adolescents). The promotional and educational material is aligned with the main objectives of the Volunteer Registry to increase public literacy and awareness regarding vaccine-related clinical research or trials and trial participation, including informed consent and legal issues, side effects, and frequently asked questions regarding vaccine trial design. Methods: Tools were developed per the aims and principles of the VACCELERATE project, focusing on trial inclusiveness and equity, and are adjusted to local country-wise requirements to improve public health communication. The produced tools are selected based on the cognitive theory, inclusiveness, and equity of differently aged and underrepresented groups, and standardized material from several official trustworthy sources (eg, COVID-19 Vaccines Global Access; the European Centre for Disease Prevention and Control; the European Patients’ Academy on Therapeutic Innovation; Gavi, the Vaccine Alliance; and the World Health Organization). A team of multidisciplinary specialists (infectious diseases, vaccine research, medicine, and education) edited and reviewed the subtitles and scripts of the educational videos, extended brochures, interactive cards, and puzzles. Graphic designers selected the color palette, audio settings, and dubbing for the video story-tales and implemented QR codes. Results: This study presents the first set of harmonized promotional and educational materials and tools (ie, educational cards, educational and promotional videos, extended brochures, flyers, posters, and puzzles) for vaccine clinical research (eg, COVID-19 vaccines). These tools inform the public about possible benefits and disadvantages of trial participation and build confidence among participants about the safety and efficacy of COVID-19 vaccines and the health care system. This material has been translated into several languages and is intended to be freely and easily accessible to facilitate dissemination among VACCELERATE network participant countries and the European and global scientific, industrial, and public community. Conclusions: The produced material could help fill knowledge gaps of health care personnel, providing the appropriate future patient education for vaccine trials, and tackling vaccine hesitancy and parents’ concerns for potential participation of children in vaccine trials.

11 April 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MPMaria Gonzalez Perez
Maria Gonzalez Perez
JBJana Baranda
Jana Baranda
MBMarcos J. Berges-Buxeda
Marcos J. Berges-Buxeda
PCPatricia Conde
Patricia Conde
Mayte Perez-OlmedaMayte Perez-Olmeda
Mayte Perez-Olmeda
JOJordi Ochando
Jordi Ochando
Continuous evaluation of the coronavirus disease 2019 (COVID-19) vaccine effectiveness in hemodialysis (HD) patients is critical in this immunocompromised patient group with higher mortality rates due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The response towards vaccination in HD patients has been studied weeks after their first and second SARS-CoV-2 vaccination dose administration, but no further studies have been developed in a long-term manner, especially including both the humoral and cellular immune response. Longitudinal studies that monitor the immune response to COVID-19 vaccination in individuals undergoing HD are therefore necessary to prioritize vaccination strategies and minimize the pathogenic effects of SARS-CoV-2 in this high-risk group of patients. We followed up HD patients and healthy volunteers (HV) and monitored their humoral and cellular immune response three months after the second (V2+3M) and after the third vaccination dose (V3+3M), taking into consideration previous COVID-19 infections. Our cellular immunity results show that, while HD patients and HV individuals secrete comparable levels of IFN-γ and IL-2 in ex vivo stimulated whole blood at V2+3M in both naïve and COVID-19-recovered individuals, HD patients secrete higher levels of IFN-γ and IL-2 than HV at V3+3M. This is mainly due to a decay in the cellular immune response in HV individuals after the third dose. In contrast, our humoral immunity results show similar IgG binding antibody units (BAU) between HD patients and HV individuals at V3+3M, independently of their previous infection status. Overall, our results indicate that HD patients maintain strong cellular and humoral immune responses after repeated 1273-mRNA SARS-CoV-2 vaccinations over time. The data also highlights significant differences between cellular and humoral immunity after SARS-CoV-2 vaccination, which emphasizes the importance of monitoring both arms of the immune response in the immunocompromised population.

21 November 2022 in JMIR Preprints
Verified
Preprint
Open access
Christos D. ArgyropoulosChristos D. Argyropoulos
Christos D. Argyropoulos
JLJanina Leckler
Janina Leckler
JSJon Salmanton-García
Jon Salmanton-García
MCMarinos Constantinou
Marinos Constantinou
AAAlexandra Alexandrou
Alexandra Alexandrou
Zoi Dorothea PanaZoi Dorothea Pana
Zoi Dorothea Pana
BACKGROUND The pan-European VACCELERATE network aims to implement the first transnational harmonized and sustainable vaccine trial Volunteer Registry, being a single entry point for potential volunteers of large-scale vaccine trials across Europe. This work exhibits a set of harmonized vaccine trial–related educational and promotional tools for the general public, designed and disseminated by the pan-European VACCELERATE network. OBJECTIVE This study primarily aimed to design and develop a standard toolkit to increase positive attitudes and access to trustworthy information for better access and increased recruitment to vaccine trials for the public. More specifically, the produced tools are focused on inclusiveness and equity, and are targeting different population groups, including underserved ones, as potential volunteers for the VACCELERATE Volunteer Registry (older individuals, migrants, children, and adolescents). The promotional and educational material is aligned with the main objectives of the Volunteer Registry to increase public literacy and awareness regarding vaccine-related clinical research or trials and trial participation, including informed consent and legal issues, side effects, and frequently asked questions regarding vaccine trial design. METHODS Tools were developed per the aims and principles of the VACCELERATE project, focusing on trial inclusiveness and equity, and are adjusted to local country-wise requirements to improve public health communication. The produced tools are selected based on the cognitive theory, inclusiveness, and equity of differently aged and underrepresented groups, and standardized material from several official trustworthy sources (eg, COVID-19 Vaccines Global Access; the European Centre for Disease Prevention and Control; the European Patients’ Academy on Therapeutic Innovation; Gavi, the Vaccine Alliance; and the World Health Organization). A team of multidisciplinary specialists (infectious diseases, vaccine research, medicine, and education) edited and reviewed the subtitles and scripts of the educational videos, extended brochures, interactive cards, and puzzles. Graphic designers selected the color palette, audio settings, and dubbing for the video story-tales and implemented QR codes. RESULTS This study presents the first set of harmonized promotional and educational materials and tools (ie, educational cards, educational and promotional videos, extended brochures, flyers, posters, and puzzles) for vaccine clinical research (eg, COVID-19 vaccines). These tools inform the public about possible benefits and disadvantages of trial participation and build confidence among participants about the safety and efficacy of COVID-19 vaccines and the health care system. This material has been translated into several languages and is intended to be freely and easily accessible to facilitate dissemination among VACCELERATE network participant countries and the European and global scientific, industrial, and public community. CONCLUSIONS The produced material could help fill knowledge gaps of health care personnel, providing the appropriate future patient education for vaccine trials, and tackling vaccine hesitancy and parents’ concerns for potential participation of children in vaccine trials.

Verified
Journal Article
Open access
PDF file
CGCristina Matilde Villa Gómez
Cristina Matilde Villa Gómez
VBVerónica Bermejo
Verónica Bermejo
IMInmaculada Márquez-Leiva
Inmaculada Márquez-Leiva
JBJana Baranda
Jana Baranda
ABAlejandro Briones
Alejandro Briones
PPPilar Portolés
Pilar Portolés
Phosphatidylinositol-3-kinases (PI3Ks) are heterodimers of catalytic and regulatory subunits that regulate cell metabolism, activation, and survival. PI3K, particularly the p110α catalytic isoform, is frequently mutated in cancer, and highly specific inhibitors such as alpelisib are currently used in oncology and in PIK3CA-related overgrowth disorders. Given the relevance of macrophages in anti-tumor immunity, we examined the impact of alpelisib on murine monocytes’ intracellular signaling and on in vitro differentiation, polarization, and effector functions of macrophages. Real-time qPCR (RT-qPCR) showed comparable relative expression of PI3K isoforms (p110α, p110β, p110δ, p110γ and p85) in bone marrow monocytes and in macrophages differentiated with macrophage colony-stimulating factor (M-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF). However, alpelisib increased p110α, p110β, and p85 relative gene expression (2–3-fold) during M-CSF-dependent differentiation. Functionally, alpelisib-treated M-CSF macrophages displayed enhanced interleukin (IL)-6 and tumor necrosis factor alpha (TNF-α) secretion and reduced IL-10 production after lipopolysaccharide (LPS) plus interferon gamma (IFN-γ) or LPS stimulation. In contrast, GM-CSF macrophages differentiated with alpelisib secreted lower levels of IL-6 and TNF-α and reduced inducible nitric oxide synthase (iNOS) and arginase-1 (Arg-1) gene expression. Additionally, cytokine profiles (IL-2, IL-6, IFN-γ and IL-10) were altered when alpelisib-treated macrophages were cocultured with CD4+ T cells under either antigen-specific or polyclonal activation conditions, indicating that the inhibitor modifies both differentiation and subsequent effector interactions of the macrophages. Thus, alpelisib induces lasting effects on macrophage differentiation and function, with potential implications in tumor-associated macrophages that develop under M-CSF or GM-CSF-rich cancer microenvironments.

9 October 2026 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
AYAndreas Yallouris
Andreas Yallouris
CFCharalampos Filippou
Charalampos Filippou
CMChristina Merakou
Christina Merakou
Christos D. ArgyropoulosChristos D. Argyropoulos
Christos D. Argyropoulos
STSophia C Themistocleous
Sophia C Themistocleous
Zoi Dorothea PanaZoi Dorothea Pana
Zoi Dorothea Pana
Background: Future health professionals are expected to recommend vaccines, communicate with patients about vaccine safety, and support clinical trial literacy and recruitment during public health emergencies. However, their own willingness to participate in vaccine trials, and the barriers that shape that willingness, remain incompletely characterized across Europe. Objective: This study aimed to assess willingness to participate in future vaccine trials among European students in health-related disciplines and to describe their perceived barriers, motivations, vaccine attitudes, and preferred sources of health information. Methods: We conducted an open, multilingual, cross-sectional web survey within the VACCELERATE network from June to November 2023. National coordinators distributed the survey through institutional mailing lists, student associations, and program channels in participating European countries. Eligible participants were students aged 18 years or older enrolled in medicine, dentistry, nursing, pharmacy, psychology, biomedical sciences, physiotherapy, occupational therapy, or other health-related programs. The questionnaire assessed demographic characteristics, primary sources of health information, vaccine attitudes, willingness to participate in future vaccine trials, barriers among unwilling or unsure respondents, and motivations for participation. Analyses were descriptive, and denominators varied by item because nonmandatory questions could be skipped. Results: Of 1381 eligible respondents, 1192 (86.3%) answered the primary willingness question: 32.9% (n=392) were willing to participate in a future vaccine trial, 38.8% (n=463) were unsure, and 28.3% (n=337) were unwilling. Among the 769 respondents who were unwilling or unsure and selected barriers, the most frequent concerns were potential side effects (n=574, 74.6%) and not wanting to be a “test subject” (n=276, 35.9%). Among 1289 respondents included in the motivation analysis, commonly selected motivators included knowing the risks and side effects involved (n=575, 44.6%), becoming part of the solution to an important health problem (n=584, 45.3%), and knowing that personal safety would be protected (n=500, 38.8%). Conclusions: In this multicountry European sample of health professional students, only one-third reported willingness to participate in future vaccine trials, while the largest group was unsure. The findings suggest that trial-readiness initiatives for future health professionals should prioritize transparent communication about safety monitoring, risks and side effects, participant protections, and the practical conduct of vaccine trials. Because recruitment used an open convenience approach, the results should be interpreted as exploratory and hypothesis generating rather than representative of all European health professional students.